NEWS BioVaxys Announces Appointment BioVaxys Announces Appointment To Its Scientific Advisory Board
VANCOUVER, B.C. , Feb. 22, 2021 /CNW/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTC: LMNGF) ("BioVaxys"), a biotechnology company that is advancing viral and oncology vaccine platforms as well as immuno-diagnostic products, today announced the appointment of Kartik Chandran Ph.D., to its Scientific Advisory Board ("SAB").
Dr. Chandran is a professor of microbiology and immunology and the Harold and Muriel Block Scholar in Virology at Albert Einstein College of Medicine in New York City , where he oversees a team of researchers engaged in basic and translational research on emerging RNA virusesand investigating the molecular mechanisms of infection. Dr. Chandran's laboratory focuses on coronaviruses and filoviruses, including SARS-CoV-2, Ebola virus, and Marburg virus, and other neglected emerging viruses such as hantaviruses and Crimean-Congo hemorrhagic fever virus, and leads a multi-institutional collaboration to discover and develop potent, long-lasting antibody treatments against these viruses. Dr. Chandran received his Ph.D. in Biochemistry at theUniversity of Wisconsin-Madison , followed by research fellowships at Harvard Medical Schooland Brigham and Women's Hospital prior to joining Einstein.
"We are pleased to welcome Dr. Chandran to our Scientific Advisory Board. As a leading virologist and immunologist, he will provide valuable insight as we work to advance our haptenized viral vaccine platform in targeting life-threatening viral diseases," commented Ken Kovan, President and Chief Operating Officer of BioVaxys. Kovan added, "We also share common interest in exploring synthetic antigens, either to address multiple SARS-CoV-2 variants or as part of a vaccine technology to elicit a stronger immune response for other viruses."
Dr. Chandran stated, "I look forward to assisting Biovaxys in its efforts to develop new vaccines that will prepare us for future viral outbreaks." BioVaxys has developed its vaccine technology platforms based on the established immunological concept that modifying proteins with simple chemicals called haptens makes them more visible to the immune system. The process of haptenization "teaches" a patient's immune system to recognize and make target proteins more 'visible' as foreign, thereby stimulating an immune response.
About BioVaxys Technology Corp.
Based in Vancouver , BioVaxys Technology Corp . is a British Columbia -registered, early stage biotechnology company that is developing viral and oncology vaccine platforms, as well as immuno-diagnostics. The Company is advancing a SARS-CoV-2 vaccine based on its haptenized viral protein technology and is planning a clinical trial of its haptenized autologous cell vaccine used in combination with anti-PD1 and anti-PDL-1 checkpoint inhibitors that will initially be developed for ovarian cancer. Also in development is a diagnostic for evaluating the presence or absence of a T cell immune response to SARS-CoV-2, the virus that causes COVID-19. BioVaxys has two issued US patents and two patent applications related to its cancer vaccine, and pending patent applications for its SARS-CoV-2 (Covid-19) vaccine and diagnostic technologies. BioVaxys common shares are listed on the CSE under the stock symbol "BIOV" and trade on the Frankfurt Bourse (FRA: 5LB) and US OTC: LMNGF.
ON BEHALF OF THE BOARD
Signed " James Passin "
James Passin , CEO
+1 646 452 7054
Media Contacts
Nikita Sashdev
Luna PR
info@lunapr.io